Evidence map›Paper›PMID 38324395›Full record

ArticleBiochemistry2024

Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.

Vito F Palmisano, Claudio Agnorelli, Andrea Fagiolini, David Erritzoe, David Nutt, Shirin Faraji, Juan J Nogueira

Abstract read
In one paragraph

Article in Biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The working lives of neuronal 5-HTRSC chemical biology · 2026
    Review
  2. Psychedelic therapy and postpartum depression: priorities and prospects.Therapeutic advances in psychopharmacology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vito F PalmisanoDepartment of Chemistry, Universidad Autonoma de Madrid, Madrid 28049, Spain.
Claudio AgnorelliCenter for Psychedelic Research, Division of Psychiatry, Department of Brain Science, Imperial College of London, London SW7 2BX, U.K.
Andrea FagioliniUnit of Psychiatry, Department of Molecular Medicine, University of Siena, Siena 53100, Italy.
David ErritzoeCenter for Psychedelic Research, Division of Psychiatry, Department of Brain Science, Imperial College of London, London SW7 2BX, U.K.
David NuttCenter for Psychedelic Research, Division of Psychiatry, Department of Brain Science, Imperial College of London, London SW7 2BX, U.K.
Shirin FarajiTheoretical Chemistry Group, Zernike Institute for Advanced Materials, University of Groningen, Groningen 9747 AG, The Netherlands.
Juan J NogueiraDepartment of Chemistry, Universidad Autonoma de Madrid, Madrid 28049, Spain.ORCID 0000-0001-7419-5670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renewed scientific interest in psychedelic compounds represents one of the most promising avenues for addressing the current burden of mental health disorders. Classic psychedelics are a group of compounds that exhibit structural similarities to the naturally occurring neurotransmitter serotonin (5-HT). Acting on the 5-HT type 2A receptors (HT

Identifiers

PMID38324395
PMCPMC10882957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.